Bevacizumab, a VEGF-targeted humanized IgG1 antibody, was approved for the treatment of colorectal cancer (CRC), non-small cell lung carcinoma (NSCLC), and glioblastoma in China. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.